S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
NASDAQ:TCRX

Tscan Therapeutics Stock Forecast, Price & News

$7.02
-0.64 (-8.36%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.01
$7.69
50-Day Range
$6.17
$9.05
52-Week Range
$6.06
$14.71
Volume
22,864 shs
Average Volume
71,142 shs
Market Capitalization
$166.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive TCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Tscan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Tscan Therapeutics logo

About Tscan Therapeutics

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

Headlines

Tscan Therapeutics (NASDAQ:TCRX) Posts Earnings Results
November 11, 2021 |  americanbankingnews.com
Tscan Therapeutics Inc
September 20, 2021 |  reuters.com
TScan Therapeutics, Inc. Common Stock (TCRX)
August 23, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRX
Phone
N/A
Fax
N/A
Employees
61
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.09 million
Book Value
$7.26 per share

Profitability

Net Income
$-26.13 million
Net Margins
-522.54%
Pretax Margin
-522.54%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$166.85 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/09/2022

MarketRank

Overall MarketRank

2.24 out of 5 stars

Medical Sector

479th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

78th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -












Tscan Therapeutics (NASDAQ:TCRX) Frequently Asked Questions

Is Tscan Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tscan Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tscan Therapeutics stock.
View analyst ratings for Tscan Therapeutics
or view top-rated stocks.

Are investors shorting Tscan Therapeutics?

Tscan Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 68,200 shares, an increase of 32.2% from the October 31st total of 51,600 shares. Based on an average daily volume of 70,600 shares, the short-interest ratio is currently 1.0 days. Approximately 0.7% of the shares of the stock are sold short.
View Tscan Therapeutics' Short Interest
.

When is Tscan Therapeutics' next earnings date?

Tscan Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Tscan Therapeutics
.

How were Tscan Therapeutics' earnings last quarter?

Tscan Therapeutics, Inc. (NASDAQ:TCRX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.19. The firm earned $2.41 million during the quarter. Tscan Therapeutics had a negative net margin of 522.54% and a negative trailing twelve-month return on equity of 779.91%.
View Tscan Therapeutics' earnings history
.

What price target have analysts set for TCRX?

4 Wall Street analysts have issued 1-year target prices for Tscan Therapeutics' stock. Their forecasts range from $21.00 to $22.00. On average, they expect Tscan Therapeutics' share price to reach $21.67 in the next year. This suggests a possible upside of 208.6% from the stock's current price.
View analysts' price targets for Tscan Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Tscan Therapeutics IPO?

(TCRX) raised $100 million in an initial public offering on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

What is Tscan Therapeutics' stock symbol?

Tscan Therapeutics trades on the NASDAQ under the ticker symbol "TCRX."

When does Tscan Therapeutics' lock-up period expire?

Tscan Therapeutics' lock-up period expires on Wednesday, January 12th. Tscan Therapeutics had issued 6,666,667 shares in its IPO on July 16th. The total size of the offering was $100,000,005 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Tscan Therapeutics' major shareholders?

Tscan Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.26%), RA Capital Management L.P. (5.24%), DC Funds LP (2.63%), Wellington Management Group LLP (0.58%), Monashee Investment Management LLC (0.42%) and Caas Capital Management LP (0.31%). Company insiders that own Tscan Therapeutics stock include Brian M Silver, Gavin Macbeath and Zoran Zdraveski.
View institutional ownership trends for Tscan Therapeutics
.

Which institutional investors are buying Tscan Therapeutics stock?

TCRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., RA Capital Management L.P., DC Funds LP, Wellington Management Group LLP, Monashee Investment Management LLC, Caas Capital Management LP, DC Investments Management LLC, and Millennium Management LLC. Company insiders that have bought Tscan Therapeutics stock in the last two years include Brian M Silver, Gavin Macbeath, and Zoran Zdraveski.
View insider buying and selling activity for Tscan Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Tscan Therapeutics?

Shares of TCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tscan Therapeutics' stock price today?

One share of TCRX stock can currently be purchased for approximately $7.02.

How much money does Tscan Therapeutics make?

Tscan Therapeutics has a market capitalization of $166.85 million and generates $1.09 million in revenue each year.

How many employees does Tscan Therapeutics have?

Tscan Therapeutics employs 61 workers across the globe.

What is Tscan Therapeutics' official website?

The official website for Tscan Therapeutics is www.tscan.com.

Where are Tscan Therapeutics' headquarters?

Tscan Therapeutics is headquartered at 830 WINTER STREET, WALTHAM MA, 02451.

How can I contact Tscan Therapeutics?

Tscan Therapeutics' mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The company can be reached via email at [email protected].


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.